Nu-Med Plus (NUMD) Cash from Operations Growth (1y) (2013 - 2025)
Nu-Med Plus (NUMD) Cash from Operations Growth (1y) (2013 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.26 Bn | 175.96 Bn | 6.27 Bn | -7.20% |
| 2 | Stryker | 128.79 Bn | 125.92 Bn | 3.81 Bn | 132.40% |
| 3 | Medtronic | 108.56 Bn | 99.34 Bn | 6.41 Bn | 1.78% |
| 4 | Boston Scientific | 68.31 Bn | 66.86 Bn | 3.61 Bn | -35.67% |
| 5 | Edwards Lifesciences | 47.27 Bn | 43.60 Bn | 1.29 Bn | -84.38% |
| 6 | Dexcom | 28.42 Bn | 27.31 Bn | 750.30 Mn | 185.96% |
| 7 | GE HealthCare Technologies | 28.40 Bn | 26.12 Bn | 1.98 Bn | 16.00% |
| 8 | Smith & Nephew | 26.95 Bn | 26.37 Bn | - | - |
| 9 | Koninklijke Philips | 25.52 Bn | 22.40 Bn | 2.07 Bn | 122.43% |
| 10 | Nu-Med Plus | 1.67 Mn | 1.67 Mn | - | -2,001.56% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2,001.56% |
| Dec 31, 2024 | 61.05% |
| Jun 30, 2024 | 89.97% |
| Mar 31, 2024 | 97.77% |
| Dec 31, 2023 | 82.47% |
| Sep 30, 2023 | -3,104.62% |
| Jun 30, 2023 | -809.42% |
| Mar 31, 2023 | -66.14% |
| Dec 31, 2022 | -21.17% |
| Sep 30, 2022 | 101.53% |
| Jun 30, 2022 | 96.18% |
| Mar 31, 2022 | 84.68% |
| Dec 31, 2021 | 71.70% |
| Sep 30, 2021 | 59.42% |
| Jun 30, 2021 | 54.91% |
| Mar 31, 2021 | 16.75% |
| Dec 31, 2020 | 42.85% |
| Sep 30, 2020 | -33.87% |
| Jun 30, 2020 | -22.25% |
| Mar 31, 2020 | 61.41% |